Not admitted · Commitment (own venture)
Rules 1.1.0 · as of 14 Sep 2026
Rick Doblin · Said 2 Dec 2019 · doblin-0099
Quote
Commitment (own venture)
“The interim analysis for our first Phase 3 study is going to take place in March 2020. We expect to begin enrolling for the second Phase 3 study for FDA and the Phase 3 study for EMA in April or May 2020, pending regulatory clearances. If the studies remain on schedule, we anticipate the New Drug Application will be submitted to the FDA in 2021 and the Marketing Authorization Application to EMA in 2022.”
Projections for FY2019-20 in the annual financial report co-written by Merete Christiansen and Rick Doblin.
The forecaster's own organization can make the outcome happen by its own decision: clinic openings, product launches, hires, trial starts, filings by their own company. Listed in the commitments table, never scored.